1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Rapid and accurate point-of-care testing for SARS-CoV2 antibodies

Sally Esmail¹, Michael J. Knauer², Husam Abdoh², Benjamin Chin-Yee³, Peter Stogios⁵,
Almagul Seitova⁴, Ashley Hutchinson⁴, Farhad Yusifov⁴, Tatiana Skarina⁵, Elena
Evdokimova⁵, Suzanne Ackloo⁴, Lori Lowes², Courtney Voss¹, Benjamin D. Hedley², Vipin
Bhayana², Ian Chin-Yee² and Shawn S-C. Li^{1*}

¹Departments of Biochemistry, Schulich School of Medicine and Dentistry, Western
University, London, Ontario N6G 2V4, Canada;

²Department of Pathology and Laboratory Medicine and ³Divison of Hematology, Western
University and London Health Sciences Centre, 800 Commissioners Rd E, London, Ontario
N6A 5W9, Canada;

⁴Structural Genomics Consortium, University of Toronto, 101 College St, MaRS South
Tower, Suite 700, Toronto, Ontario M5G 1L7, Canada;

⁵Department of Chemical Engineering and Applied Chemistry, University of Toronto, 200
College St., Toronto, Ontario M5S 3E5, Canada.

*Corresponding author: sli@uwo.ca

24 **ABSTRACT**

25

26 The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2
 27 (SARS-CoV-2), has grown into worst public health crisis since the 1918 influenza pandemic.
 28 As COVID-19 continues to spread around the world, there is urgent need for a rapid, yet
 29 accurate antibody test to identify infected individuals in populations to inform health
 30 decisions. We have developed a rapid, accurate and cost-effective serologic test based on
 31 antibody-dependent agglutination of antigen-coated latex particles, which uses ~5 µl plasma
 32 and takes <5 min to complete with no instrument required. The simplicity of this test makes it
 33 ideal for point-of-care (POC) use at the community level. When validated using plasma
 34 samples that are positive or negative for SARS-CoV-2, the agglutination assay detected
 35 antibodies against the receptor-binding domain of the spike (S-RBD) or the nucleocapsid (N)
 36 protein of SARS-CoV-2 with 100% specificity and ~98% sensitivity. Furthermore, we found
 37 that the strength of the S-RBD antibody response measured by the agglutination assay
 38 correlated with the efficiency of the plasma in blocking RBD binding to the angiotensin
 39 converting enzyme 2 (ACE2) in a surrogate neutralization assay, suggesting that the
 40 agglutination assay may be used to identify individuals with virus-neutralizing antibodies.
 41 Intriguingly, we found that >92% of patients had detectable antibodies on the day of positive
 42 viral RNA test, suggesting that seroconversion may occur earlier than previously thought and
 43 that the agglutination antibody test may complement RNA testing for POC diagnosis of
 44 SARS-CoV-2 infection.

45

46 INTRODUCTION

47

48 Development of rapid point-of-care COVID-19 diagnostics for use at the community level
 49 remains a top priority in the global response to the COVID-19 pandemic¹. While capacity for
 50 detecting SARS-CoV-2 based on nucleic acid amplification (NAAT) has grown immensely
 51 and enabled effective public health responses, serologic testing for virus specific antibodies
 52 has not gained the same widespread application, due to concerns over sensitivity, specificity,
 53 cost and turn-around time^{1,2}. Although NAAT is the current gold standard for diagnosing
 54 acute infection, it is not effective in identifying individuals who have recovered from
 55 previous infection³. Given that approximately 40% of infected individuals remain
 56 asymptomatic^{1,4,5}, large-scale antibody testing could help better establish the true extent of
 57 the COVID-19 pandemic, identifying disease hotspots and high-risk populations to enable
 58 more effective isolation and contact tracing^{1,3,6}. Moreover, antibody testing may identify
 59 individuals with a strong neutralizing antibody response who may be suitable donors for
 60 convalescent plasma/serum therapy for the treatment of those with severe symptoms⁷.

61

62 To date, a number of antibody tests have been approved for emergency use in the US and
 63 Europe. These tests detect the IgG, IgM or IgA antibody against the spike (including the
 64 receptor binding domain, RBD) or nucleocapsid (N) protein of the SARS-CoV-2 virus by
 65 enzyme-linked immunosorbent assay (ELISA)³. ELISA-based antibody tests, which can be
 66 qualitative or quantitative, require specialized instruments and are usually performed in a lab
 67 by a trained technician. The sensitivity and specificity of different ELISA kits vary widely⁸⁻¹⁰.
 68 To enable point-of-care (POC) testing, several rapid diagnostic tests (RDTs) based on lateral
 69 flow have been developed. Although the RDTs reduced the time of the antibody test to 10-30
 70 minutes from 2-5 hours (for ELISA), they generally suffer from decreased sensitivity and
 71 specificity compared to ELISA-based assays^{1,11-13}.

72

73 To address the pressing need for a simple, rapid, yet accurate antibody test¹, we resorted to the
 74 tested-and-proven serology method of agglutination that has been used in blood typing and
 75 antibody testing¹⁴⁻¹⁶. We show here that the agglutination of red blood cells (RBCs) or latex
 76 particles induced by specific antigen-antibody interaction affords a highly sensitive and
 77 accurate assay for SARS-CoV-2 antibodies. We validated the antibody assay based on latex
 78 particle agglutination using 169 plasma samples that were tested positive for SARS-CoV-2 by

79 NAAT, 121 samples that were NAAT negative and 100 SARS-CoV-2 naïve plasma samples.
80 The agglutination-based antibody assay produced 100% specificity and 97-98.2% sensitivity.
81 Because this simple assay requires no instrument and generates results in 2 minutes, it has the
82 potential to be used as a POC or at-home test.

83

84 **RESULTS**

85

86 **Agglutination-based serologic testing for SARS-CoV-2 antibodies**

87

88 Agglutination of RBCs is widely used in blood typing whereas latex particle agglutination
89 assays have been used to detect antibodies against a variety of different viruses. We sought to
90 establish whether either or both approaches could be adapted for SARS-CoV-2 antibody
91 testing. In principle, coating the RBCs or the latex particles with a SARS-CoV-2 specific
92 antigen would enable their respective agglutination by the corresponding antibody (Fig. 1).
93 To explore this notion, we labelled Group O (R2R2) RBCs carrying the D antigen with the
94 spike RBD (S-RBD) or the RNA binding domain of the nucleocapsid (N-RBD) protein
95 through streptavidin-biotin mediated coupling (Figs. S1 & S2, see Materials and Methods for
96 details). Incubating the antigen-coated RBCs with COVID-19⁺ plasma led to robust
97 agglutination whereas the COVID-19⁻ plasma failed to induce RBC agglutination, suggesting
98 that the aggregation of the S-RBD/N-RBD-coated RBCs may be used to detect antibody
99 response to SARS-CoV-2 (Fig. S2).

100

101 To develop a cost-effective agglutination assay, we next investigated if latex particles were a
102 suitable substitute for the RBCs. To this end, we coated latex particles with recombinant
103 S-RBD or the full-length nucleocapsid (N) protein (Fig. S1). The antigen coated latex beads
104 were first tested with a monoclonal anti-S-RBD and a polyclonal anti-nucleocapsid antibody.
105 Upon incubating with the corresponding antibody, the antigen-coated latex particles formed
106 clumps within two minutes. Importantly, the area of clump formation grew larger with
107 increasing antibody concentrations (Fig. S3). Although latex agglutination was commonly
108 used as a qualitative assay, it is possible to determine the degree of agglutination based on the
109 area of clump formation via image analysis. As shown in Fig. 2, the percentage of
110 agglutination for both the S-RBD- and N-coated latex particles increased when an
111 incremental amount of anti-S-RBD or anti-N antibody was added. Fitting the data to Hill's

equation yielded Hill's coefficient of 1.7 for the former and 1.8 for the latter. This suggests that the antibody-induced agglutination of latex particles is a cooperative event (Fig. 2A&B).

We next examined if the latex agglutination assay could be used to gauge COVID-19 antibody response. Using plasma samples from patients tested positive for SARS-CoV-2 by NAAT and confirmed for strong antibody response by ELISA, we found that the patient plasma samples were not only capable of inducing agglutination of the S-RBD- or N-coated latex particles, they did so in a concentration-dependent manner. As shown in Fig. 2C&D, the extent of agglutination decreased as the plasma was diluted, indicating that the agglutination assay may be used to estimate antibody titer as in an ELISA-based antibody test.

The latex agglutination-based antibody assay showed high sensitivity and specificity

To validate the antibody test based on latex particle agglutination, we carried out agglutination assays for 290 residual plasma samples from individuals that were tested positive (169) or negative (121) for virus RNA by the Roche cobas SARS-CoV-2 test⁹. To assess specificity, we also included 100 virus-naïve samples banked in 2018 in our agglutination assay. None of the 121 SARS-CoV-2⁻ or the 100 Pre-COVID-19 plasma samples was capable of promoting the agglutination of either the S-RBD- or N-coated latex particles, indicating 100% specificity for the agglutination assay (Table 1). In contrast, of the 169 SARS-CoV-2⁺ plasma samples tested, 166 (98.2%) promoted agglutination in response to the S-RBD antigen and 164 (97%) to the N antigen, with overall sensitivity of 98.2%. We compared the latex agglutination assay with the Euroimmune IgG test for the S antibody and the Roche Elecsys® Total assay for the N antibody using the same set of SARS-CoV-2⁺ plasma samples and found that the latex agglutination assay outperformed both ELISA-based antibody tests (Table 2). The agglutination assay also exhibited better specificity than either ELISA kit (Table 2). Quantification of the agglutination data showed that the COVID-19⁺ group is significantly different from the COVID-19⁻ or pre-COVID-19 group, indicating that the latex agglutination assay effectively distinguished SARS-CoV2⁺ from SARS-CoV2⁻ individuals (Fig. 3A&B).

Based on the background signals of the COVID-19⁻ samples (0-4% agglutination for both S-RBD- and N-coated latex particles), we set 5% agglutination as the cut-off for antibody positivity. To facilitate the use of the latex agglutination assay as a simple, semi-quantitative

antibody test, we developed a numerical scoring system for antibody response. We assigned the scores 1, 2, 3 and 4 to samples that produced 5-25%, 25-50%, 50-75% and >75% agglutination, respectively (Fig. S4). We found that this scoring scheme effectively distinguished samples with strong antibody response from those with medium or weak ones (Fig. 3C&D). The agglutination score may be readily assigned by visual inspection and comparing to reference wells containing a predetermined amount of pure anti-S-RBD or anti-N antibody (Fig. S3).

The S-RBD antibody response correlated with neutralizing antibody titer

Because neutralizing antibodies (Nab) play a pivotal role in the humoral immune response to the virus¹⁷, we next examined if the S-RBD antibody response determined by the agglutination assay correlated with neutralization efficiency. We developed a surrogate neutralization assay by measuring the efficacy of patient plasma in blocking S-RBD binding to its host receptor, angiotensin converting enzyme 2 (ACE2) *in vitro*. Similar approaches have been used by others to evaluate neutralization efficiency of patient plasma or therapeutic antibodies^{18,19}. Briefly, binding of biotinylated ACE2 to immobilized S-RBD is detected by ELISA through HRP-conjugated streptavidin. The presence of neutralizing antibody would block this interaction, resulting in reduction of the ELISA signal. Using this surrogate neutralization assay, we found that the neutralization efficiency increased with the agglutination score for the S-RBD antibody (Fig. 4A). Intriguingly, comparison of samples with distinct S-RBD and N antibody responses indicated that the neutralization efficiency was significantly correlated with the S-RBD, but not the N antibody strength. This is not surprising given that the nucleocapsid is not involved in mediating virus entry into the host cells via ACE2. Nevertheless, it remains to be determined if the plasma with strong N antibody response would confer immunity by inhibiting virus replication *in vivo*.

The agglutination assay allowed for early antibody detection and tracking of dynamic antibody response

We noted that the agglutination assay detected antibody response in >92% plasma samples collected on the day of SARS-CoV2⁺ diagnosis by NAAT and in 100% samples on day 2 and afterward. This is in stark contrast to the 47% to 83% sensitivity for ELISA-based antibody tests on samples collected within 7 days of positive NAAT⁹. The superb sensitivity of the

latex agglutination assay suggests that it may be used to detect antibody response in the early stage of virus infection and monitor its dynamic changes over time^{12,20,21}. Using serial blood samples from SARS-CoV-2⁺ patients, we compared the changes in the S-RBD and N antibody responses between days 1 and day 3 (Fig. 4C&D). We found that the majority of patients showed detectable S-RBD and/or N antibodies on NAAT⁺ day 1. Moreover, the antibody titer increased significantly on day 3 compared to day 1. Because it is not possible to determine how long these patients had contracted the virus prior to the NAAT test, seroconversion might have occurred for some on the day of diagnosis. Nevertheless, we were able to detect anti-S-RBD or anti-N antibodies on day 3 for several patients who showed no detectable antibody on day 1, suggesting seroconversion occurred rapidly in these patients⁴. Taken together, these data suggest that the latex agglutination assay may be used to diagnose active infection in conjunction with NAAT. Combined antibody and RNA testing may increase the sensitivity of the later. Moreover, the agglutination-based antibody test may be used to monitor the evolvement of humoral immune reaction in infected individuals over time.

DISCUSSION

Antibody testing offers an additional and much needed tool for managing the COVID-19 pandemic, which may allow for rapid and cost-effective POC diagnosis to facilitate treatment and public health responses. Furthermore, antibody testing may play an important role in identifying individuals who have gained protective immunity from previous exposure or immunization programs. While the clinical trial results for several vaccine candidates are encouraging, seroconversion is unlikely to occur for all vaccinated individuals²². A highly sensitive and specific antibody test would allow for accurate assessment of humoral response to a vaccine, and serial testing post-vaccination could indicate the duration of humoral immunity against SARS-CoV-2. Such information will be invaluable to inform public health decisions, both for directing resource allocation and determining response to vaccination.

While most serology tests used in the clinic are specific for a specific antibody isoform, IgG, IgM or IgA, the latex agglutination antibody assay is, in principle, isotope-independent¹¹. This may contribute to its high sensitivity, especially on samples collected in the early phase of infection when IgG isotope switching has not yet occurred. It has been shown that the IgM antibody response proceeds that of IgG^{3,11}, and the pentameric architecture of IgM may make

it a stronger promoter of agglutination than IgG. Moreover, the agglutination assay detects antibodies against the spike (S) and the nucleocapsid (N) in parallel whereas most existing assays are specific for either protein. These factors explain why the agglutination assay could detect antibody in >92% plasma samples collected on the day of NAAT⁺ diagnosis and 100% on day 2 and onwards whereas other antibody tests were less sensitive. The ability of our assay to detect antibodies at the early stages of infection suggests that it may be used to complement or confirm the diagnosis based on NAAT, which is prone to false positives or false negatives especially when done only once²³.

Several features of the agglutination assay make it an ideal candidate for POC or at-home antibody testing. First, the assay is highly sensitive and accurate, with 100% specificity and ~98% sensitivity on the samples tested in this study. Importantly, it detected antibodies in >92% COVID-19 patients on the day of diagnosis. This sensitivity rivals that of NAAT tests²³. Second, the agglutination test is fast. It takes two minutes from mixing the plasma with the latex particles to getting the result. Third, the agglutination assay is simple to run and instrument-free. As the formation of latex bead clumps is easy to identify by the naked eye, the test may be performed without extensive specialized training. Fourth, because the agglutination assay takes only ~5 µl plasma, it may be developed into a finger prick blood test suitable for at-home use. Finally, the low cost of the latex agglutination assay makes it universally affordable and ideal for antibody testing at the community or population level, in high- and low-resource settings alike.

ACKNOWLEDGEMENT

We thank the Center for Structural Genomics of Infectious Diseases (CDGID) for the N-RBD expression plasmid, Dr. Jason McLellan for expression plasmid for human ACE2, Dr. Shane Harding for the spike-receptor binding domain expression construct, and Yanjun Li for technical assistance. This work was supported by a grant (to SSCL, ICY, MK, BCY and VB) from the Ontario Research Fund-COVID-19 Rapid Research Fund and by the Toronto COVID-19 Action Fund. SE was supported by a Post-Doctoral Fellowship from the National Science and Engineering Council of Canada. SSCL held a Canada Research Chair in Molecular and Epigenetic Basis of Cancer.

Table 1: Clinical performance of the agglutination-based antibody assay

Samples	Anti-S-RBD (n)		Anti-N (n)		Overall Sensitivity	Overall Specificity
	Positive	Negative	Positive	Negative		
SARS-CoV-2 NAAT positive (n=169)	166	3	164	5	98.2% (166/169)	
Days of SARS-CoV-2 NAAT positive						
1 (n=41)	38	3	36	5	92.7% (38/41)	
2 (n=31)	30	1	31	0	100%	
≥3 (n=97)	97	0	96	1	100%	
SARS-CoV-2 NAAT negative (n=121)	0	121	0	121		100%
Pre-COVID-19 (n=100)	0	100	0	100		100%

Table 2: Comparison in sensitivity and specificity between the agglutination-based and ELISA-based antibody assays

Anti-S (RBD)	Agglutination assay (n)		ELISA ⁹ EUROIMMUNE (n)		Sensitivity (Agglutination)	Sensitivity (Euroimmune)	Specificity (Agglutination)	Specificity (Euroimmune)
	Positive	Negative	Positive	Negative				
SARS-CoV-2 NAAT positive (n=121)	118	3	90	31	97.5% (118/121)	74.4% (90/121)	NA	
SARS-CoV-2 NAAT Negative & preCOVID-19	0	221	11	194	NA		100% (221/221)	94.6% (194/205)
Anti-N	Agglutination assay (n)		ELISA ⁹ Roche Elecsys® (n)		Sensitivity (Agglutination)	Sensitivity (Roche)	Specificity (Agglutination)	Specificity (Roche)
	Positive	Negative	Positive	Negative				
SARS-CoV-2 NAAT positive (n=69)	68	1	66	2	98.6% (68/69)	95.7% (66/69)	NA	
SARS-CoV-2 NAAT Negative & preCOVID-19	0	221	1	135	NA		100% (221/221)	99% (135/136)

FIGURE LEGENDS

Figure 1. Illustration of the principle of agglutination assay for SARS-CoV-2 antibody testing.

(A) Latex particles or red blood cells (RBCs) are surface-coated with a SARS-CoV-2 antigen, the S-RBD or nucleocapsid (N). Incubation with plasma containing antibodies against the coated antigen would induce agglutination of the latex particles or RBCs. (B) A representative image of the agglutination assay using latex beads coated with S-RBD.

Figure 2. Antibody-induced latex particle agglutination correlates with the antibody titer.

(A, B) Changes in agglutination in response to increased concentrations of the anti-S-RBD (n=3) or anti-N antibody (n=3). Dash lines represent fitted curves to Hill equation (h, Hill coefficient). (C, D) S-RBD (C) or N (D) antibody-induced agglutination decreased with increased dilution of plasma. Shown are agglutination data (in log₂ scale) from three COVID-19⁺ plasma samples with 1:2 to 1:128 dilution (three replicates/concentration).

Figure 3. Agglutination assay distinguished COVID-19⁺ from COVID-19⁻ samples.

(A, B) Comparison of S-RBD (A) and N antibody responses between COVID-19⁺ (n=169), COVID-19⁻ (n=121) and Pre-COVID-19 (n=100) samples determined by the aggregation assay. (C, D) The strength of the S-RBD and N antibody response in the COVID-19⁺ (n=169) plasma samples could be determined semi-quantitatively by the aggregation score (1-4 denotes weak-to-strong antibody response). Statistical analyses were performed using unpaired Student's t-test with Welch's correction (p values shown on graph).

Figure 4. Using the latex agglutination assay to determine neutralizing antibody titer and dynamic changes in antibody response.

(A) Neutralization antibody response correlated significantly with the agglutination score. P values calculated based on unpaired Student t-test (n=10 for each group). (B) Spearman (r) correlation of efficiency of neutralization and S-RBD or N antibody response (n=25). (C, D) Dynamic changes in

antibody responses in COVID-19 patients. n=20 for day 1 and n=20 for day 3; p-values calculated based on unpaired Student's t-test with Welch's correction.

MATERIALS AND METHODS

Blood sample collection

Blood samples were collected following a protocol (study number: 116284) approved by the Research Ethics Board (REB) of Western University. The plasma samples were de-identified prior to transfer from the Laboratory of Clinical Medicine (London Health Sciences Center, London, Canada) to a biosafety Level 3 (CL3) lab (ImPaKT, Western University) following Transportation of Dangerous Goods (TDG) guidelines. All plasma samples were heat-inactivated at 56 °C for 30 minutes at the ImPaKT CL3 facility as per Western university biosafety regulation. Heat inactivated plasma samples were then transferred to the testing laboratory. We tested the effect of heat inactivation on SARS-CoV-2 antibody titer and found no significant impact of heat-inactivation (see also Fig. S5).

Recombinant protein production and purification

The expression plasmid for human ACE2 cloned into the mammalian expression vector pαH (residues 1–615 with a C-terminal HRV3C protease cleavage site, a TwinStrepTag and an 8XHisTag) was a generous gift by Dr. McLellan. SARS-CoV-2 S-RBD cloned into pCAGGs the expression vector was received from Dr. Harding's lab. SARS-CoV-2 N-RBD was cloned into the pMCSG53 prokaryotic expression vector (residues 47-173-terminal 6x-His tag + TEV protease cleavage site).

Recombinant ACE2 and S-RBD proteins were produced by transient transfection of Expi293F cells (ThermoFisher Scientific, A14527) with a corresponding expression vectors and FectoPRO® DNA transfection reagent (Polyplus-transfection® SA, Cat. #116-010). Supernatants from transfected cells were harvested after 96 hours of the post-transfection time by centrifugation of the culture at 65,000 RPM for 30 min at 4°C. Cleared supernatant was then incubated with 4 ml TALON® Metal Affinity Resin (Takara Bio USA, Inc. Cat#635652) for 2h at 4°C. Ni-NTA chromatography was used to purify His-tagged recombinant proteins. Each protein was dialyzed and concentrated in Amicon centrifugal units (EMD Millipore) in a final

buffer of 20mM HEPES (pH 7.5, 200mM NaCl, pH 7.5, 5% glycerol).

Recombinant N-RBD was expressed in *E. coli* BL21(DE3)-Gold. Ni-NTA chromatography and size exclusion chromatography-Superdex S200 was used to purify N-RBD. The tag was cleaved using TEV followed by dialysis. The N-RBD protein was resuspended in 0.1 M NaCl, 20 mM HEPES pH 7.5 and stored at -80 °C until use. Recombinant nucleocapsid (residues 1-419) was obtained from RayBiotech (Cat #230-01104). Protein purity was confirmed by SDS-PAGE (Fig. S1).

Preparation of SARS-CoV-2 antigen coated latex particles

Blue dyed polystyrene latex beads, 0.8 μ m in diameter, were purchased from Sigma Aldrich (L1398). Prior to use, the latex beads were washed according to the manufacturer's instructions with some modifications. Briefly, 2.5mL of 5% (w/v) latex suspension was washed twice in 10 mL PBS buffer (135 mM NaCl, 2.6 mM KCl, 8 mM Na₂HPO₄, and 1.5 mM KH₂PO₄, pH 7.4) by mixing and centrifuging the latex suspension at 3,000g for 10 minutes at room temperature. The beads were then resuspended with 2.5 ml 0.025M MES buffer (2-(N-Morpholino) ethanesulfonic acid, pH 6.0) to obtain 5% (w/v) suspension.

SARS-CoV-2 antigen-latex particle conjugates were prepared by passive adsorption following the procedures described by Mahat et al²⁴, with some modifications. Briefly, 0.4 mL of 5% (w/v) latex suspension was centrifuged at 3,000 g for 5 minutes at room temperature, and the supernatant was discarded. The beads were incubated with 200 μ g recombinant Receptor Binding Domain of the SARS-CoV-2 spike protein (S-RBD) (Structural Genomics Consortium, University of Toronto) or the Nucleocapsid protein (N protein) (RayBiotech, 230-01104) in 4 mL MES buffer. The mixture was allowed to incubate for 24 hours at 4°C with periodic mixing. After conjugation, the antigen-latex bead conjugate was centrifuged, and the supernatant was kept for determination of unabsorbed protein concentration (Bio-Rad protein assay kit). The antigen-bead conjugate was washed twice with PBS and blocked for 30 min at room temperature in PBS containing 3% bovine serum albumin (BSA). The conjugate was then resuspended at 2.5% (w/v) in PBS containing 1% BSA and stored at 4°C until use.

Agglutination assay for SARS-CoV-2 antibody testing and data interpretation

347

348 For the agglutination assay, 5 μ l plasma was mixed with 25 μ l antigen-coated beads (2.5%,
349 w/v) per assay. The agglutination was allowed to proceed for 2 min at room temperature
350 before imaging with a camera. The relative degree of agglutination induced by the
351 SARS-CoV-2 antibody was measured by the area of clump formation based on the
352 corresponding image. Agglutination data analyses were performed using qualitative and
353 semi-quantitative assessments. For semi-quantification of agglutination, the image analysis
354 software Qupath (v0.1.2) was used (<https://qupath.github.io/>) and quantification was done by
355 calculating the percentage of agglutination based on estimated agglutination/clumps area
356 (mm^2) relative to the total latex reaction area. In qualitative assessments, agglutination
357 intensity was inspected visually, and agglutination score was assigned (i.e. 1, 2, 3 and 4).
358 Specifically, 1 corresponds to small clumps with ~25% agglutination, 2 (~50% agglutination),
359 3 (~75% agglutination), and 4 (large clumps that forms in less than 1 min with ~100%
360 agglutination). Based on data from the COVID-19 negative samples (including NAAT
361 negative and samples collected in 2018), the cut-off for positivity was set to 5% of
362 agglutination.

363 **Preparation of red blood cells conjugated with SARS-CoV-2 antigen**

364 The recombinant spike receptor-binding domain (S-RBD) or the nucleocapsid RNA-binding
365 domain (N-RBD) was conjugated in 30-fold molar excess biotin using EZ-Link
366 Sulfo-NHS-LC-LC-Biotin (Thermo Scientific, A35358). Excess unbound biotin was removed
367 using ZebaTM Spin Desalting Columns, 7KMWCO (Thermo Scientific, 89890). Anti-D-IgG
368 was purified from Immucor Anti-D Series 4 (IgG & IgM monoclonal blend) by using protein
369 A magnetic affinity purification (G8782, Promega). The purified anti-D-IgG was then
370 concentrated (3mg/ml) and stored at 4 °C until use. Anti-D was then conjugated with
371 streptavidin according to manufacturer instruction (ab102921, abcam).

372

373 Bioconjugation of Anti-D-IgG-streptavidin with Reagent Red Blood Cells (RRBC) [0.8%
374 R2R2; blood group O; Rh/D-antigen+] (Ortho-Clinical Diagnostics SELECTOGEN,
375 6902315) was done by incubating the anti-D-IgG-streptavidin with RRBC for 30 min at room
376 temperature. The RRBC-anti-D-streptavidin complex was then washed twice with low ionic
377 strength RBC diluent (MTS™ Diluent 2 PLUS; Micro Typing Inc., MTS9330S). The
378 complex was centrifuged at 1000g for 2 min to remove unbound anti-D-IgG streptavidin and

was then resuspended in the same RBC diluent. RBC-anti-D-IgG-streptavidin was then conjugated with either biotin-S-RBD or biotin-N-RBD for 15 min at room temperature. The RRBC-anti-D-streptavidin-biotin-S-RBD/N-RBD was stored at 4 °C until use. The RRBC agglutination assay was carried out in the same way as for latex agglutination described above.

S-RBD-ACE2 binding ELISA and surrogate neutralization assay

ELISA plate Coating and blocking -S-RBD was dissolved (5 µg/ml) in Tris buffer saline (TBS) (20 mM Tris, 150 mM NaCl, pH7.4) and 100 µl of the S-RBD solution was added to each well of an ELISA plate and incubate at 4°C overnight with slow shaking. The antigen-coated wells were washed 3 times with TBS-tween (TBST) (20 mM Tris, 150 mM NaCl, 0.1% Tween 20). The S-RBD coated wells were blocked by 100 µl of the ChonBlock™ blocking/sample dilution ELISA buffer (Chondrex, Inc., 9068) for 1 hour at room temperature with slow shaking followed washing 3 times with TBST.

ACE2:S-RBD binding assay- ACE2 was biotinylated as described above. Biotin-ACE2 (1µg/m) was added to S-RBD-coated plate after blocking and incubated for 1hour at room temperature. The wells were washed 3 times with TBST to remove unbound biotin-ACE2. Streptavidin-HRP (1000-fold dilution with Chonblock blocking buffer) was then added to each well and incubated for 1hour at room temperature. The wells were washed 3 times with TBST and TMB substrate (3,3',5,5'-Tetramethylbenzidine, Thermo Scientific, N301) was added for reaction development and 0.18 M H₂SO₄ was used to stop reaction. Absorbance at 450nm was measured to detect the S-RBD bound ACE2.

SARS-CoV-2 antibody neutralization assay- Plasma was diluted 1:100 and incubated with S-RBD-coated wells (blocked) for 1hour at room temperature. The wells were washed three times with TBST. Biotin-ACE2 was then added to the wells and incubated for 1 hour at room temperature followed by washing, reaction development and detection as described above.

Statistical analysis

All statistical analyses were done using the GraphPad Prism9 software. Specifically, the Hill coefficient (h) was calculated from fitting agglutination data obtained using anti-S-RBD and anti-N antibodies to the Hill equation. COVID-19⁺ samples with distinct agglutination scores

412 and COVID-19⁺ samples were analyzed using unpaired t-test with Welch's correction (no
 413 assumption of equal SD between two groups). Changes in agglutination for samples before
 414 and after heat-inactivation were analyzed by paired t-test. Spearman's correlation rank was
 415 done to study correlation between antibody titter and ACE2:S-RBD neutralization efficiency.
 416
 417

REFERENCE

- 1 Peeling, R. W. *et al.* Serology testing in the COVID-19 pandemic response. *The Lancet Infectious Diseases* **20**, e245-e249, doi:10.1016/s1473-3099(20)30517-x (2020).
- 2 Kruttgen, A. *et al.* Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG. *J Clin Virol* **128**, 104394, doi:10.1016/j.jcv.2020.104394 (2020).
- 3 Ravi, N., Cortade, D. L., Ng, E. & Wang, S. X. Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape. *Biosens Bioelectron* **165**, 112454, doi:10.1016/j.bios.2020.112454 (2020).
- 4 Amanat, F. *et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med* **26**, 1033-1036, doi:10.1038/s41591-020-0913-5 (2020).
- 5 He X, L. E., Wu P *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* **26**, 672-675 (2020).
- 6 Weisberg, S. P. *et al.* Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. *Nat Immunol*, doi:10.1038/s41590-020-00826-9 (2020).
- 7 Shen, C. *et al.* Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA* **323**, 1582-1589, doi:10.1001/jama.2020.4783 (2020).
- 8 Jaaskelainen, A. J. *et al.* Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. *J Clin Virol* **129**, 104512, doi:10.1016/j.jcv.2020.104512 (2020).
- 9 Knauer, M. J. *et al.* Interim analysis of the clinical performance of five SARS-Cov-2 serology assays. *Clin Biochem*, doi:10.1016/j.clinbiochem.2020.09.002 (2020).
- 10 Lisboa Bastos, M. *et al.* Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ* **370**, m2516, doi:10.1136/bmj.m2516 (2020).
- 11 Pavlova, I. P., Nair, S. S., Kyprianou, N. & Tewari, A. K. The Rapid Coronavirus

- 447 Antibody Test: Can We Improve Accuracy? *Front Med (Lausanne)* **7**, 569,
448 doi:10.3389/fmed.2020.00569 (2020).
- 449 12 Whitman, J. D. *et al.* Test performance evaluation of SARS-CoV-2 serological assays.
450 *medRxiv*, doi:10.1101/2020.04.25.20074856 (2020).
- 451 13 Li, Z. *et al.* Development and clinical application of a rapid IgM-IgG combined
452 antibody test for SARS-CoV-2 infection diagnosis. *J Med Virol*,
453 doi:10.1002/jmv.25727 (2020).
- 454 14 Gupta, A. & Chaudhary, V. K. Whole-blood agglutination assay for on-site detection
455 of human immunodeficiency virus infection. *J Clin Microbiol* **41**, 2814-2821,
456 doi:10.1128/jcm.41.7.2814-2821.2003 (2003).
- 457 15 Hursh DA, A. A., Sun R, Iltis JP, Rice DH and Gleaves CA. Evaluation of a Latex
458 Particle Agglutination Assay for the Detection of Cytomegalovirus Antibody in
459 Patient Serum. *J. Clin. Microbiol*, 2878-2879 (1989).
- 460 16 Alves, D. *et al.* Rapid Gel Card Agglutination Assays for Serological Analysis
461 Following SARS-CoV-2 Infection in Humans. *ACS Sens* **5**, 2596-2603,
462 doi:10.1021/acssensors.0c01050 (2020).
- 463 17 Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and
464 Other Human Coronaviruses. *Trends Immunol* **41**, 355-359,
465 doi:10.1016/j.it.2020.03.007 (2020).
- 466 18 Tortorici MA, B. M., Lempp FA, Pinto D, Dang HV, Rosen LE, McCallum M, Bowen
467 J, Minola A, Jaconi S, Zatta F, De Marco A, Guarino B, Bianchi S, Lauron EJ, Tucker
468 H, Zhou J, Peter A, Havenar-Daughton C, Wojcechowskyj JA, Case JB, Chen RE,
469 Kaiser H, Montiel-Ruiz M, Meury M, Czudnochowski N, Spreafico R, Dillen J, Ng C,
470 Sprugasci N, Culap K, Benigni F, Abdelnabi R, Foo SC, Schmid MA, Cameroni E,
471 Riva A, Gabrieli A, Galli M, Pizzuto MS, Neyts J, Diamond MS, Virgin HW, Snell G,
472 Corti D, Fink K, Veessler D. . Ultrapotent human antibodies protect against
473 SARS-CoV-2 challenge via multiple mechanisms. *Science*, 2020 Sep 2024:eabe3354.
474 doi: 10.1126/science.abe3354. Epub ahead of print. PMID: 32972994. (2020).

475 19 Abe, K. T. *et al.* A simple protein-based surrogate neutralization assay for
476 SARS-CoV-2. *JCI Insight* **5**, doi:10.1172/jci.insight.142362 (2020).

477 20 Robbani, D. F. *et al.* Convergent Antibody Responses to SARS-CoV-2 Infection in
478 Convalescent Individuals. *bioRxiv*, doi:10.1101/2020.05.13.092619 (2020).

479 21 Qu, J. *et al.* Profile of IgG and IgM antibodies against severe acute respiratory
480 syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis*, doi:10.1093/cid/ciaa489
481 (2020).

482 22 Thanh Le, T. *et al.* The COVID-19 vaccine development landscape. *Nat Rev Drug*
483 *Discov* **19**, 305-306, doi:10.1038/d41573-020-00073-5 (2020).

484 23 Jarrom, D. *et al.* Effectiveness of tests to detect the presence of SARS-CoV-2 virus,
485 and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic
486 review. *BMJ Evid Based Med*, doi:10.1136/bmjebm-2020-111511 (2020).

487 24 Mahat, M., Abdullah, W. Z. & Che Hussin, C. M. Conventional rapid latex
488 agglutination in estimation of von Willebrand factor: method revisited and potential
489 clinical applications. *Journal of immunology research* **2014** (2014).
490
491

A

B

Figure 1: Illustration of the principle of agglutination assay for SARS-CoV-2 antibody testing. (A) Latex particles or red blood cells(RBC) are surface-coated with a SARS-CoV-2 antigen, the S-RBD or nucleocapsid (N). Incubation with plasma containing antibodies against the coated antigen would induce agglutination of the latex particles or RBCs. (B) A representative image of the agglutination assay using latex beads coated with S-RBD.

Figure 2. Antibody-induced latex particle agglutination correlates with the antibody titer. (A, B) Changes in agglutination in response to increased concentrations of the anti-S-RBD ($n=3$) or anti-N antibody ($n=3$). Dash lines represent fitted curves to Hill equation (h , Hill coefficient). (C, D) S-RBD (C) or N (D) antibody-induced agglutination decreased with increased dilution of plasma. Shown are agglutination data (in $\log_2$ scale) from three COVID-19+ plasma samples with 1:2 to 1:128 dilution. Data shown are from three replicates per concentration.

Figure 4. Using the latex agglutination assay to determine neutralizing antibody titer and dynamic changes in antibody response. (A) Neutralization antibody response correlated significantly with the agglutination score. P values calculated based on unpaired Student t-test ($n=10$ for each group). (B) Spearman (r) correlation of efficiency of neutralization and S-RBD or N antibody response ($n=25$). (C, D) Dynamic changes in antibody responses in COVID-19 patients. $n=20$ for day 1 and $n=20$ for day 3; p-values calculated based on unpaired Student's t-test with Welch's correction.

Supplementary Figures

Rapid and accurate point-of-care testing for SARS-CoV2 antibodies

Sally Esmail¹, Michael J. Knauer², Husam Abdoh², Benjamin Chin-Yee³, Peter Stogios⁵, Almagul Seitova⁴, Ashley Hutchinson⁴, Farhad Yusifov⁴, Tatiana Skarina⁵, Elena Evdokimova⁵, Suzanne Ackloo⁴, Lori Lowes², Courtney Voss¹, Benjamin D. Hedley², Vipin Bhayana², Ian Chin-Yee² and Shawn S-C. Li^{1*}

¹Departments of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario N6G 2V4, Canada;

²Department of Pathology and Laboratory Medicine and ³Divison of Hematology, Western University and London Health Sciences Centre, 800 Commissioners Rd E, London, Ontario N6A 5W9, Canada;

⁴Structural Genomics Consortium, University of Toronto, 101 College St, MaRS South Tower, Suite 700, Toronto, Ontario M5G 1L7, Canada;

⁵Department of Chemical Engineering and Applied Chemistry, University of Toronto, 200 College St., Toronto, Ontario M5S 3E5, Canada.

*Corresponding author: sli@uwo.ca

Esmail et al.

Figure S1. SDS-PAGE images of recombinant SARS-CoV-2 proteins employed in the current study.

Esmail et al.

Figure S2. SARS-CoV2 antibody testing based on RBC agglutination.

Red blood cells (RBC, group O; R2R2) carrying the D antigen were labelled with anti-D IgG conjugated to recombinant S-RBD or N-RBD through streptavidin-biotin (i.e., IgG-streptavidin conjugated to biotin-RBD). (A) S-RBD labeled RBCs were mixed with either SARS-CoV-2⁻ (NAAT) or SARS-CoV2⁺ plasma (right). (B) N-RBD labeled RBCs were mixed with either SARS-CoV2⁻ (left) or SARS-CoV2⁺ plasma (right). Images shown were taken after 1 min incubation at room temperature.

Esmail et al.

Figure S3. Agglutination of blue latex particles in response to different concentrations of antibody (IgG) against the nucleocapsid (αN) or S-RBD (αS-RBD). Anti-S-RBD (monoclonal, NBP2-90980) was obtained from Novus Biologicals; Anti-Nucleocapsid (polyclonal, PA5-81794) was from ThermoFisher Scientific.

Esmail et al.

Figure S4. Representative images of agglutination induced by plasma with different agglutination scores. Shown are five samples with distinct agglutination scores (0-4) in the nucleocapsid (αN) (upper row) or the S-RBD antibody ($\alpha S-RBD$) test (lower row). The scores were assigned as 4 = 75-100% agglutination; 3 = 50-75% agglutination; 2 = 25-50% agglutination; 1 = 5-25% agglutination; 0 (or negative) $\leq 5\%$ agglutination.

Esmail et al.

Figure S5. Heat inactivation of plasma did not affect antibody induced agglutination. Shown are agglutination percentages between samples without or with heat-inactivation in the anti-S-RBD (left) or anti-N (right) agglutination assay. p-values calculated from paired two tailed t-test (no assumption of equal variance, n=6).